Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 3/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2192069 | 0.95 | RAB9A (0.48) | NTRK1MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL2190947 | 0.88 | NTRK1 (0.54) | NTRK1MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL1505089 | 0.80 | KDR (0.56) | EGFR | |
| SCHEMBL1504837 | 0.80 | NTRK1 (0.53) | NTRK1MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL25002181 | 0.77 | RAB9A (0.77) | MEN1KMT2ARAB9ANPC1CSNK1D | |
| SCHEMBL3945407 | 0.75 | KDR (0.54) | NTRK1EGFR | |
| SCHEMBL1504863 | 0.73 | KDR (0.58) | EGFR | |
| 4Sc-203 SCHEMBL1505017 | 0.72 | EGFR (0.64) | EGFR | |
| 4Sc-203 SCHEMBL29370845 | 0.72 | EGFR (0.64) | EGFR | |
| SCHEMBL3943812 | 0.72 | EPHX2 (0.58) | NTRK1MEN1KMT2ARAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172241-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110172241-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20110172241-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2011-07-14 | — | — | US | disclosed |
| US-20090270410-A1 | BENZAZOLE ANALOGUES AND USES THEREOF | 4SC AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270410-A1 | BENZAZOLE ANALOGUES AND USES THEREOF | 4SC AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270410-A1 | BENZAZOLE ANALOGUES AND USES THEREOF | 4SC AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-7576090-B2 | e.g. N-[2-(6,7-Dimethoxyquinazolin-4-ylamino)benzothiazol-6-yl ]benzamide; multi-target protein kinase, especially epidermal and endothrlial growth factor, inhibitors; antiproliferative, anticarcinogenic agent | 4SC AG (DE) | 2009-08-18 | — | — | US | disclosed |
| US-7576090-B2 | e.g. N-[2-(6,7-Dimethoxyquinazolin-4-ylamino)benzothiazol-6-yl ]benzamide; multi-target protein kinase, especially epidermal and endothrlial growth factor, inhibitors; antiproliferative, anticarcinogenic agent | 4SC AG (DE) | 2009-08-18 | — | — | US | disclosed |
| US-7576090-B2 | e.g. N-[2-(6,7-Dimethoxyquinazolin-4-ylamino)benzothiazol-6-yl ]benzamide; multi-target protein kinase, especially epidermal and endothrlial growth factor, inhibitors; antiproliferative, anticarcinogenic agent | 4SC AG (DE) | 2009-08-18 | — | — | US | disclosed |
| EP-1833823-A1 | 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE ANALOGUES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006069740-A1 | 2, 5 AND 2, 6-DISUBSTITUTED BENZAZOLE ANALOGUES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2006-07-06 | — | — | WO | disclosed |
| US-20060142570-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142570-A1 | Benzazole analogues and uses thereof | CYP3A5, CYP3A7, CYP3A43 | NTRK1 4453/4885MEN1 2616/4885KMT2A 3416/4885 |
| US-20110172241-A1 | Benzazole analogues and uses thereof | CYP3A5, CYP3A7, CYP3A43 | NTRK1 4453/4885MEN1 2616/4885KMT2A 3416/4885 |
| US-20090270410-A1 | BENZAZOLE ANALOGUES AND USES THEREOF | CYP3A5, CYP3A7, CYP3A43 | NTRK1 4296/4885MEN1 2688/4885KMT2A 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.